Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies
JAMA Network Open · 27.08.2024 · 7 (8) · e2430486
DOI: 10.1001/jamanetworkopen.2024.30486 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 27.08.2024. Verfasst von Maryam Mooghali und 3 weiteren Autor:innen. Beteiligte Einrichtung: Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Drug Approval, Product Surveillance, Postmarketing. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAAA NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Importance The US Food and Drug Administration (FDA) awards the breakthrough therapy designation to expedite development and review of therapeutics intended to treat serious conditions when preliminary clinical evidence demonstrates potential substantial improvement over existing therapies on clinically significant end points. Under the 21st Century Cures Act of 2016, the FDA is required to publish and routinely update a list of surrogate markers to provide industry sponsors with indication-specific information about end points that were or may be considered for approval. Therapeutics that are granted breakthrough therapy designation can receive accelerated or traditional approval; however, little is known about those approved through the latter pathway, where postmarketing confirmatory studies are typically not required, regardless of the end point used.
Objective
To evaluate the primary end points used in premarket pivotal trials supporting FDA breakthrough therapy–designated approvals and to determine whether postmarketing studies confirming efficacy were required for approvals based on pivotal trials using surrogate markers as primary end points. Design, Setting, and Participants This cross-sectional study used data from the Drugs@FDA database for all original breakthrough therapy–designated approvals from inception to December 31, 2023, in the US. The first designation was approved on November 1, 2013. Data analysis was performed in January 2024. Main Outcomes and Measures Descriptive analyses were used to characterize the breakthrough therapy–designated indication approval pathways, the primary end points of pivotal efficacy trials, and their postmarketing requirements or commitments.
Results
From 2013 to 2023, the FDA approved 157 original indications with breakthrough therapy designation. Of these, 52 (33%) were granted accelerated approval and 105 (67%) were granted traditional approval. All accelerated approvals were based on pivotal trials using surrogate markers as primary end points and had FDA-required postmarketing studies to confirm efficacy. Of these 52 indications, 51 (98%) were approved based on surrogate end points listed in the FDA table of surrogate end points for the same indication. Among traditional approvals, 61 (58%) were based on pivotal trials using surrogate markers as primary end points, of which 4 (7%) had FDA-required postmarketing studies to confirm efficacy and 39 (64%) were approved based on surrogate end points listed in the FDA table for the same indication. Conclusions and Relevance In this cross-sectional study of original FDA breakthrough therapy–designated approvals from 2013 to 2023, trials supporting these approvals often used surrogate markers as primary end points (even when not approved via accelerated approval) and lacked FDA-required postmarketing studies to verify clinical benefit. These findings suggest that requiring postmarketing studies for breakthrough therapy–designated indications approved based on surrogate markers, regardless of approval pathway, may increase patient and clinician certainty of the expected clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
- Yale Collaboration for Regulatory Rigor, Integrity and Transparency, Yale School of Medicine, New Haven, Connecticut.
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.
- Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
- Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut.
Förderung
- NIAAA NIH HHS
- NCATS NIH HHS
Zitieren
APA
Mooghali, M., Wallach, J. D., Ross, J. S., & Ramachandran, R. (2024). Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies. JAMA Network Open, 7(8), e2430486. https://doi.org/10.1001/jamanetworkopen.2024.30486
Vancouver
Mooghali M, Wallach JD, Ross JS, Ramachandran R. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies. JAMA Network Open. 2024;7(8):e2430486. doi:10.1001/jamanetworkopen.2024.30486
BibTeX
@article{Mooghali2024,
author = {Mooghali, Maryam and Wallach, Joshua D and Ross, Joseph S and Ramachandran, Reshma},
title = {Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {8},
pages = {e2430486},
doi = {10.1001/jamanetworkopen.2024.30486}
}
EUVIMED